We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Risk Factors Predict Outcomes for Children with Hypertrophic Cardiomyopathy

By LabMedica International staff writers
Posted on 18 Sep 2013
The risk of death or need for immediate listing for heart transplantation for hypertrophic cardiomyopathy (HCM) was greatest for those who developed the disease as infants with congestive heart failure, and for children who also had selective inborn errors of metabolism.

A group of rare genetic disorders, in which one or more of the body's key metabolic processes are disrupted, help predict outcomes for children with this heart condition called hypertrophic cardiomyopathy (HCM). More...
This condition, a type of pediatric cardiomyopathy with varied causes and outcomes, is characterized by increased hypertrophy of the heart wall.

In the United States, HCM is rare, with fewer than one out of 100,000 children (ages birth to 18 years old) diagnosed annually The condition is more frequently diagnosed in infants (under the age of one year), with 2 to 3 out of every 100,000 identified each year.

Scientists from the University of Miami Miller School of Medicine (Miami, FL, USA) and colleagues from other institutions, sought to understand how risk factors at the time of HCM diagnosis are predictors of death or the need to be added to a heart transplantation waiting list. They spent 19 years amassing data on more than 1,000 affected children at 98 pediatric cardiology centers in the US and Canada through the NHLBI-funded Pediatric Cardiomyopathy Registry.

The findings were published online in September 2013 in the Lancet to coincide with a presentation at the European Society of Cardiology Congress 2013 meeting in Amsterdam (The Netherlands). The National Heart, Lung, and Blood Institute (NHLBI) and the Children's Cardiomyopathy Foundation supported this research.

Related Links:
University of Miami Miller School of Medicine




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.